deliv result thursday morn sale right in-lin
last month pre-announce somewhat better bottom-lin vs
conserv ep forecast import note fact sell-
side analyst updat forecast follow pre-announce headlin
miss gener expect buy-sid today base discuss
start top-lin sale report organ in-
line jpme strength rtg vs jpme
diabet off-set headwind mitg cvg
busi bottom line cash ep came
expect much better gross margin
sg in-lin major med-tech name
manag chose provid guidanc
updat estim forecast point toward sale
report organ cash ep sale
earn report organ
sourc style exposur morgan quantit deriv strategi tabl compani data morgan estim
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
summari invest thesi valuat
past year weve seen signific turnaround
perform manag return
consist exceed expect importantli
materi improv gener
stick point mani investor set
notabl disrupt compani outlook near-
term see exposur middl
road given divers compani end market
mix product line could even see
tailwind on-going crisi like diabet respiratori
patient monitor extracorpor life support
expect see signific de-lever near-term
compani priorit abil return growth post-
sell-off weve seen sinc start
year disproportion compani exposur
view coupl multipl pipelin updat tap
later remain bullish medtron outlook
reiter overweight rate
dec price target share
base calendar price-to-earnings multipl slight discount
large-cap med-tech peer set appli calendar
million
cash-flow oper
margin growth
 morgan quantit deriv strategi perform driver compani data bloomberg morgan estim tabl
invest thesi valuat risk
past year weve seen signific turnaround perform
manag return consist exceed expect
importantli materi improv gener stick
point mani investor set notabl disrupt
compani outlook near-term see exposur
middl road given divers compani end market
mix product line could even see tailwind on-going crisi like
diabet respiratori patient monitor extracorpor life support
expect see signific de-lever near-term compani priorit
abil return growth sell-off weve seen sinc start
year disproportion compani exposur view
coupl multipl pipelin updat tap later remain bullish
medtron outlook reiter overweight rate
dec price target share base calendar price-to-earnings
multipl slight discount large-cap med-tech peer set appli
calendar ep estim see appropri given compani in-
line outlook longer term off-set modest headwind near term
risk rate price
downsid risk includ slower growth and/or increas competit core end
market slower anticip adopt new technolog poor
deploy capit lack gener
medtron plc summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end apr o/w
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect research analyst person view subject secur issuer
part research analyst compens directli indirectli relat specif recommend
view express research analyst report korea-bas research analyst list front cover applic
also certifi per kofia requir analysi made good faith view reflect opinion
without undu influenc intervent
author name within report research analyst unless otherwis specifi europ sector specialist may shown
report contact author report part research depart
